Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B. Johnson, Christine M. Lovly, Riley Ennis et al.|Cancer Immunology Research|2016Cited by 493
<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal CancerJeremy Jones, Axel Grothey, Lindsay A. Renfro et al.|Journal of Clinical Oncology|2017Cited by 357
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 TherapyL. Dousset, Lise Boussemart, F. Poizeau et al.|JCO Precision Oncology|2021Cited by 61